Limited stage diffuse large B-cell lymphoma: comparative effectiveness of treatment strategies in a large cohort of elderly patients

References

• Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood 2006;107:265–276.
   PubMed Web of Science ®Google Scholar
• Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 1998;339:21–26.
   PubMed Web of Science ®Google Scholar
• Shenkier TN, Voss N, Fairey R, et al. Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency. J Clin Oncology 2002;20:197–204.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005;23:5027–5033.
   PubMed Web of Science ®Google Scholar
• Persky DO, Unger JM, Spier CM, et al. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol 2008;26:2258–2263.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trümper L, Österborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379–391.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Brière J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.
   PubMed Web of Science ®Google Scholar
• Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 2005;23:4117–4126.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood 2010;116:2040–2045.
   PubMed Web of Science ®Google Scholar
• Zelenetz AD, Abramson JS, Advani RH, et al. Non-Hodgkin's Lymphomas. J Natl Compr Cancer Netw 2011;9:484–560.
   PubMed Web of Science ®Google Scholar
• Reyes F, Lepage E, Ganem G, et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 2005;352:1197–1205.
   PubMed Web of Science ®Google Scholar
• Bonnet C, Fillet G, Mounier N, et al. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 2007;25:787–792.
   PubMed Web of Science ®Google Scholar
• Horning SJ, Weller E, Kim K, et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group Study 1484. J Clin Oncol 2004;22:3032–3038.
   PubMed Web of Science ®Google Scholar
• Miller TP, LeBlanc M, Spier C, et al. CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkin's lymphomas: update of the Southwest Oncology Group (SWOG) randomized trial. Blood 2001;98(Suppl. 1): Abstract 3024.
   Google Scholar
• Dumontet C, Mounier N, Munck JN, et al. Factors predictive of early death in patients receiving high-dose CHOP (ACVB regimen) for aggressive non-Hodgkin's lymphoma: a GELA study. Br J Haematol 2002;118:210–217.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. About the SEER program. Available from: http://seer.cancer.gov/about/
   Google Scholar
• Potosky AL, Riley GF, Lubitz JD, et al. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care 1993;31:732–748.
   PubMed Web of Science ®Google Scholar
• North American Association of Central Cancer Registries. Guidelines for ICD-O-3 implementation. Available from: http://facs/org/cancer/coc/naaccr.pdf/
   Google Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613–619.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987;40:373–383.
   PubMedGoogle Scholar
• Klabunde CN, Potosky AL, Legler JM, et al. Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000;53:1258–1267.
   PubMed Web of Science ®Google Scholar
• Davidoff AJ, Tang M, Seal B, et al. Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 2010;28:2191–2197.
   PubMed Web of Science ®Google Scholar
• Griffiths R, Mikhael J, Gleeson M, et al. Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma. Blood 2011;118: 4808–4816.
   PubMed Web of Science ®Google Scholar
• Davidoff AJ, Hurria A, Zuckerman IH, et al. A novel approach to improve health status measurement in observational claims-based studies of cancer treatment and outcomes. J Geriatr Oncol 2013;4: 157–165.
   PubMed Web of Science ®Google Scholar
• Earle CC, Nattinger AB, Potosky AL, et al. Identifying cancer relapse using SEER-Medicare data. Med Care 2002;40:IV–75–81.
   Web of Science ®Google Scholar
• Link BK, Brooks J, Wright K, et al. Diffuse large B-cell lymphoma in the elderly: diffusion of treatment with rituximab and survival advances with and without anthracyclines. Leuk Lymphoma 2011; 52:994–1002.
   PubMed Web of Science ®Google Scholar
• Grann VR, Hershman D, Jacobson JS, et al. Outcomes and diffusion of doxorubicin-based chemotherapy among elderly patients with aggressive non-Hodgkin lymphoma. Cancer 2006; 107:1530–1541.
   PubMed Web of Science ®Google Scholar
• Avilés A, Delgado S, Ruiz H, et al. Treatment of non-Hodgkin's lymphoma of Waldeyer's ring: radiotherapy versus chemotherapy versus combined therapy. Eur J Cancer B Oral Oncol 1996;32:19–23.
   Google Scholar
• Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011;46:399–424.
   PubMed Web of Science ®Google Scholar
• Cochran WG. The effectiveness of adjustment by subclassification in removing bias in observational studies. Biometrics 1968;24:295–313.
   PubMed Web of Science ®Google Scholar
• A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987–994.
   PubMed Web of Science ®Google Scholar
• Hassett MJ, Ritzwoller DP, Taback N, et al. Validating billing/encounter codes as indicators of lung, colorectal, breast, and prostate cancer recurrence using 2 large contemporary cohorts. Med Care 2012 Dec 6. [Epub ahead of print]
   Web of Science ®Google Scholar
• Sox HC. Defining comparative effectiveness research: the importance of getting it right. Med Care 2010;48:S7–S8.
   PubMed Web of Science ®Google Scholar